Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials

  • Martin Koenighofer St. Anna Children’s Hospital, Vienna, Austria.
  • Thomas Lion Children’s Cancer Research Institute and Lab DiaLabordiagnostik, Vienna, Austria.
  • Angelika Bodenteich Marinomed Biotechnologie GmbH, Vienna, Austria.
  • Eva Prieschl-Grassauer 4Marinomed Biotechnologie GmbH, Vienna, Austria.
  • Andreas Grassauer Marinomed Biotechnologie GmbH, Vienna, Austria.
  • Hermann Unger Laboratory of Tropical Veterinary Medicine, Veterinary University Vienna, Vienna, Austria.
  • Christian A. Mueller Laboratory of Tropical Veterinary Medicine, Veterinary University Vienna, Vienna,, Austria.
  • Tamás Fazekas | tamas.fazekas@aon.at St. Anna Children’s Hospital, Vienna, Austria.

Abstract

Background: Clinical trials applying iota-carrageenan nasal spray have previously shown to reduce duration of virus-confirmed common cold. The present study pooled data of two similar clinical trials to provide further evidence for the antiviral effectiveness of carrageenan.

Methods: Individual patient data were analyzed from two randomized double blind placebo controlled trials assessing the therapeutic effectiveness of carrageenan nasal spray in acute common cold. Patients with virus-confirmed common cold (n = 254, verum 126, placebo 128) were included and the following parameters were appraised: duration of disease, number of patients with relapses, number of respiratory viruses and viral titers at inclusion (visit 1) compared to days 3–5 (visit 2).

Results: Carrageenan treated patients showed a significant reduction in duration of disease of almost 2 days (p < 0.05) as well as significantly fewer relapses during 21 days of observation period (p < 0.05). The virus clearance between visit 1 and visit 2 was significantly more pronounced in the carrageenan group (p < 0.05). In both studies, virus-confirmed common cold was caused by three main virus subtypes: human rhinovirus (46%), human coronavirus (25%) and influenza A (14%) virus. Carrageenan nasal spray showed significant antiviral efficacy in all three virus subgroups, the highest effectiveness was observed in human corona virus-infected patients. The reduced duration of disease was 3 days (p < 0.01) and the number of relapses was three times less (p < 0.01) in carrageenan treated corona-virus-infected patients compared to control patients.

Conclusions: Administration of carrageenan nasal spray in children as well as in adults suffering from virus-confirmed common cold reduced duration of disease, increased viral clearance and reduced relapses of symptoms. Carrageenan nasal spray appeared as an effective treatment of common cold in children and adults.

Trial registration: Pooled data from ISRCTN52519535 and ISRCTN80148028

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2014-11-14
Info
Issue
Section
Original Research Articles
Keywords:
Carrageenan, Common cold, Coronavirus, Respiratory disease, Rhinovirus, Influenza, Virus
Statistics
  • Abstract views: 136

  • PDF: 81
  • HTML: 8
How to Cite
Koenighofer, M., Lion, T., Bodenteich, A., Prieschl-Grassauer, E., Grassauer, A., Unger, H., Mueller, C. A., & Fazekas, T. (2014). Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials. Multidisciplinary Respiratory Medicine, 9(1). https://doi.org/10.4081/mrm.2014.392